Pf-gp6, a 6 kDa anti-degranulation glycoprotein purified from the extract of Perilla frutescens, was examined for its antiviral activity against HIV-1 and HIV-2 in vitro. HIV-1-induced cytopathic effect and proviral DNA synthesis were inhibited in the presence of Pf-gp6. The 50% inhibitory concentrations of Pf-gp6 for various HIV-1 strains, including clinical isolates and CCR5-using (R5) HIV-1, ranged between 1.3 and 71.0 μg/ml, depending on the combination of viral strain and host cell. Furthermore, Pf-gp6 did not directly inactivate infectious viral particles. A time-of-addition experiment revealed that Pf-gp6 lost its activity before zidovudine but after the CXCR-4 antagonist AMD3100 during the early stage of viral infection. Although the pinpoint target of Pf-gp6 remains to be elucidated, it may interfere with a step between viral entry and reverse transcription.
AdachiAGendelmanHEKoenigSForksTWilleyRRabsonA & MartinMA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology59: 284–291.
2.
AsadaMFukumoriYInoueMNakagomiKSugieMFujitaYTomizukaNYamazakiY & OkaS (1999) Glycoprotein derived from the hot water extract of mint plant, Perilla frutescens Britton. Journal of Agricultural and Food Chemistry47: 468–472.
3.
CalabreseCBermanSHBabishJGMaXShintoLDorrMWellsKWennerCA & StandishLJ (2000) A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytotherapy Research14: 333–338.
4.
De ClercqEYamamotoNPauwelsRBabaMScholsDNakashimaHBalzriniJMurrerBASchwartzDThorntonDBridgerGFrickerSHensonGAbramsM & PickerD (1992) Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proceedings of the National Academy of Sciences USA89: 5286–5290.
5.
DoranzBJGrovit-FerbasKSharronMPMaoSHGoetzMBDaarESDomsRW & O'BrienWA (1997) A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. Journal of Experimental Medicine186: 1395–1400.
6.
DragicTTrkolaAThompsonDACormierEGKajumoFAMaxwellELinSWYingWSmithSOSakmarTP & MooreJP (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences USA97: 5639–5644.
7.
El-MekkawySMeselhyMRNakamuraNTezukaYHattoriMKakiuchiNShimotohnoKKawahataT & OtakeT (1998) Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry49: 1651–1657.
8.
KimptonJ & EmermanM (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosi-dase gene. Journal of Virology66: 2232–2239.
9.
KoyanagiYMilesSMitsuyasuRTMerrillJEVintersHV & ChenISY (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science236: 819–822.
10.
LarderBADarbyG & RichmanDD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science243: 1731–1734.
11.
MartinITurcoSJEpandRM & RuysschaertJM (1998) Lipophosphoglycan of Leishmania donovani inhibits lipid vesicle fusion induced by the N-terminal extremity of viral fusogenic simian immunodeficiency virus protein. European Journal of Biochemistry258: 150–156.
12.
MatsushitaSGuroffRobert MRuscheJKoitoAHattoriTHoshinoHJavaherianKTakatsukiK & PutneyS (1988) Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. Journal of Virology62: 2107–2114.
13.
OtakeTMoriHMorimotoMUebaNKunitaNSanoKNakaiMOkuboSYasunagaKNagaoNHiraiK & OkuboY (1990) HIV isolation and clinical markers on the seropositive subjects. Kansenshogaku Zasshi64: 1287–1294.
14.
OtakeTMoriHMorimotoMMiyanoKUebaNOishiIKunitaN & KurimuraT. (1999) Anti-HIV-1 activity of myo-inositol hexaphosphoric acid (IP6) and myo-inositol hexasulfate(IS6). Anticancer Research19: 3723–3726.
15.
RusconiSLa-Seta-CatamancioSKurtagicSGalazziMArientiDTrabattoniDWilkenJThompsonDAOffordREGalliM & ClericiM (1999) Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon g to interleukin 10 ratio without impairing cellular proliferation. AIDS Research and Human Retroviruses15: 861–867.
16.
ScholsDEsteJAHensonG & De ClercqE (1997) Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV co-receptor Fusin/CXCR-4. Antiviral Research33: 147–156.
17.
StarcichBRHahnBHShawGMMcNeelyPDModrowSWolfHParksESParksWPJosephsSFGalloRC & Wong-StaalF (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell45: 637–648.
18.
WongJKGunthardHFHavlirDVZhangZQHaaseATIgnacioCCKwokSEminiE & RichmanDD (1997) Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proceedings of the National Academy of Sciences USA94: 12574–12579.
19.
WyattR & SodroskiJ (1998) The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science280: 1884–1888.
20.
YamasakiKNakanoMKawahataTMoriHOtakeTUebaNOishiIInamiRYamaneMNakamuraMMurataH & NakanishiT (1998) Anti-HIV-1 activity of herbs in Labiatae. Biological and Pharmaceutical Bulletin21: 829–833.
